National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Overview of Analytic Approach and Results." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
66
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

BOX 4–3 Morbidity Scenarios: Neisseria meningitidis B

 

Duration

HUI

Meningitis (ICU)

ICU

2 days

0.24

Inpatient after ICU

5 days

0.28

Meningitis (no ICU)

Inpatient

5 days

0.39

Meningitis complications

Acute complications (gangrene, arthritis, heart failure, etc.)

10 days

0.27

Meningitis sequelae

Neurologic sequelae (cranial nerve damage, deafness, etc.)

(remaining lifetime)

0.60

Bacteremia/Sepsis

ICU (Waterhouse Friederichsen)

4 days

0.16

Inpatient after ICU

10 days

0.44

Bacteremia/Sepsis (no ICU)

Inpatient

5 days

0.71

Bacteremia/Sepsis—complications

Acute complications (cardiac, DIC, pneumonia, etc.)

10 days

0.59

Bacteremia/Sepsis—sequelae

Amputation, etc.

(remaining lifetime)

0.63

NOTE: ICU=intensive care unit; DIC=disseminated intravascular coagulation.

Once the morbidity scenarios were developed, the committee reviewed each health state and assigned a level in each of the seven attributes of the HUI Mark II. Box 4–2 shows the committee’s attribute scoring for one health state (ectopic pregnancy). The quality-adjustment weight for the health state was obtained by combining the scores for each attribute using the multiplicative HUI Mark II formula. Box 4–4 shows examples of the quality adjustment weights obtained for several health states.

Quality Adjustments for Average Population Health States

To measure the health benefits associated with an intervention such as the use of a new vaccine, it is necessary to compare health status with and without the intervention. The quality-adjustment weights for each condition’s morbidity scenarios (described above) are used to calculate QALYs lived without the intervention. Quality-adjustment weights reflecting the average health status of the population are used to calculate QALYs lived with the intervention. To measure the impact of mortality and lifetime impairment, life-expectancy was “quality adjusted” for the average health status of the population and discounted to its present value. For example, the life expectancy at birth is 75.5 years in the 1993 life tables used in the committee’s analysis. The discounted quality-adjusted present value of that life expectancy is 26.8 years. For a person 50 years old

Page
66
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)